Navigation Links
Celator(R) Pharmaceuticals Announces Enrollment of First Patient in Phase 2 Study with CPX-351
Date:11/18/2008

Randomized study will enroll newly diagnosed, elderly AML patients

PRINCETON, N.J., Nov. 18 /PRNewswire/ -- Celator Pharmaceuticals today announced that the first patient has been treated in a randomized Phase 2 clinical study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in patients with newly diagnosed acute myeloid leukemia (AML).

The first patient was enrolled by Eric Feldman, MD at the Weill Medical College of Cornell University and New York Presbyterian Hospital. Dr. Feldman was an investigator involved in the Phase 1 study with CPX-351 in patients with advanced leukemias. "We are pleased to be involved in this Phase 2 study based on the encouraging results seen in the Phase 1 study," said Dr. Feldman. "It's important to develop new treatment options for patients and CPX-351 incorporates two of the most active agents used in the treatment of AML."

CPX-351 is a liposomal formulation of cytarabine and daunorubicin delivered in a 5:1 molar ratio shown in preclinical studies to represent a synergistic ratio for use in combination chemotherapy. CPX-351 represents a new approach to developing drug combinations in which drug ratios are pre-selected based on synergistic anti-tumor activity observed preclinically and where the ratios are maintained in patients through Celator's proprietary CombiPlex(R) technology platform.

The Phase 2 study will be conducted in patients with newly diagnosed AML, greater than or equal to 60 but <76 years of age, who are able to tolerate intensive chemotherapy. This randomized (2:1) study is designed to compare CPX-351 to the conventional method of administering cytarabine and daunorubicin, commonly referred to as "7+3." The reference "7+3" refers to the administration days of the drugs (cytarabine is administered as a 7 day continuous infusion and daunorubicin is administered on days 1, 2 and 3). CPX-351 is administer
'/>"/>

SOURCE Celator Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Celator(R) Pharmaceuticals Announces Positive Phase 2 Results for CPX-1 in Treatment of Colorectal Cancer
2. Celator(R) Pharmaceuticals Successfully Uses Nanoparticles to Administer Hydrophobic Drug Combinations
3. Celator(R) Pharmaceuticals Reports CPX-351 Shows Anti-Cancer Activity in Leukemia Patients
4. Raptor Pharmaceuticals Corp. Announces Positive Phase IIa Clinical Study Results for Convivia(TM) Program
5. Raptor Pharmaceuticals to Collaborate with Centre Hospitalier Universitaire dAngers for Phase II Clinical Trial in Huntingtons Disease
6. VIA Pharmaceuticals Announces Positive Results of Phase 2 Studies of VIA-2291 in Patients With Serious Cardiovascular Disease
7. Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update
8. Poniard Pharmaceuticals Announces Final Top-Line Results from Phase 1 Trial Demonstrating Positive Bioavailability with Oral Picoplatin
9. VIA Pharmaceuticals Announces Conference Call and Webcast to Discuss VIA-2291 Phase 2 Data Presentations at AHA
10. Sunesis Pharmaceuticals Presents Clinical Trial Data of Voreloxin in Patients with Acute Myeloid Leukemia and Ovarian Cancer at the Chemotherapy Foundation Symposium
11. Raptor Pharmaceuticals Provides Update on Targeting Platforms
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... YORK , July 29, 2014 /PRNewswire-iReach/ -- ... the basis of products, methods, applications, end users, ... highest growth in the microbial identification market. This ... consumable costs (per test) and the time required ... and continuous technological advancements. Furthermore, genotypic methods have ...
(Date:7/29/2014)... Inc. (NASDAQ: SQNM ), a life sciences ... revenues of $39.8 million for the second quarter of ... $24.5 million for the second quarter of 2013. ... on May 30, 2014, has been accounted for as ... excluded from continuing operations for all periods. ...
(Date:7/29/2014)... , July 29, 2014  Alexza Pharmaceuticals, Inc. (Nasdaq: ... participating in two healthcare conferences during the third quarter, ... Morgan Stanley Global Healthcare 2014 Conference.  Alexza,s corporate presentation ... The details on each event are below: ... 11, 2014 in Boston , MA.  ...
Breaking Medicine Technology:Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 2Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 3Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 4Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 5Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 6Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 2Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 3Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 4Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 5Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 6Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 7Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 8Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 9Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 10Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 11Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 12Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 13Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 14Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 15Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 16Alexza Pharmaceuticals Announces Participation in Upcoming Investor Conferences 2Alexza Pharmaceuticals Announces Participation in Upcoming Investor Conferences 3
... Sept. 28 Tamir Biotechnology, Inc. (Pink Sheets: ... today that scientists supported by the National Institute ... results confirming two of our lead compounds outperformed ... and plaque reduction assay (the gold standard) for ...
... Emerging Cancer Vaccines Market: Forecasts, Developments and Pipeline Analysis, 4th Edition Now Available... -- DALLAS, September 28, ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... BitlyCB.alertResponse = function(data) { var s = ,; var first_result; // Results are keyed by longUrl, so ...
Cached Medicine Technology:New Discovery Targets Cytomegalovirus (CMV) 2New Discovery Targets Cytomegalovirus (CMV) 3New Discovery Targets Cytomegalovirus (CMV) 4Emerging Cancer Vaccines Market: Forecasts, Developments and Pipeline Analysis, 4th Edition Now Available at ReportsandReports 2Emerging Cancer Vaccines Market: Forecasts, Developments and Pipeline Analysis, 4th Edition Now Available at ReportsandReports 3Emerging Cancer Vaccines Market: Forecasts, Developments and Pipeline Analysis, 4th Edition Now Available at ReportsandReports 4Emerging Cancer Vaccines Market: Forecasts, Developments and Pipeline Analysis, 4th Edition Now Available at ReportsandReports 5Emerging Cancer Vaccines Market: Forecasts, Developments and Pipeline Analysis, 4th Edition Now Available at ReportsandReports 6Emerging Cancer Vaccines Market: Forecasts, Developments and Pipeline Analysis, 4th Edition Now Available at ReportsandReports 7Emerging Cancer Vaccines Market: Forecasts, Developments and Pipeline Analysis, 4th Edition Now Available at ReportsandReports 8Emerging Cancer Vaccines Market: Forecasts, Developments and Pipeline Analysis, 4th Edition Now Available at ReportsandReports 9
(Date:7/29/2014)... (HealthDay News) -- Want young children to embrace a ... healthy is good for them. Doing so will actually ... study suggests. "Parents and caregivers who are struggling ... off simply serving the food without saying anything about ... actually is," said study authors Michal Maimaran, of Northwestern ...
(Date:7/29/2014)... 2014 For survivors of severe combat injuries threatening ... flaps have a good record of safety and effectiveness ... issue of Plastic and Reconstructive Surgery ... Society of Plastic Surgeons (ASPS). , Experience with ... and Afghanistan shows good success rates, with no increase ...
(Date:7/29/2014)... By Randy Dotinga ... (HealthDay News) -- When most children take on a ... less of this neuro-boosting activity in kids with autism, ... with more severe symptoms of autism displayed even less ... ,"This reduced flexibility often causes difficulty when children ...
(Date:7/29/2014)... July 29, 2014 (HealthDay News) -- Although the bite ... usually heal well if left alone, an expert notes. ... of an adverse reaction to a brown recluse spider ... Tennessee Poison Center, particularly since these potentially dangerous bites ... hard for us to do nothing. The [bite] has ...
(Date:7/29/2014)... CA (PRWEB) July 29, 2014 According ... website of Time Magazine titled “From Kim’s Butt to ... Kim Kardashian’s butt is the celebrity feature most ... their features include Beyoncé’s butt, Jennifer Lawrence’s ... This information is based on data collected by an ...
Breaking Medicine News(10 mins):Health News:Kids Will Pass on 'Healthy' Foods 2Health News:Good outcomes with multiple limb salvage after severe combat injuries, reports Plastic and Reconstructive Surgery 2Health News:Less Flexibility Seen in Brain Wiring of Kids With Autism: Study 2Health News:Less Flexibility Seen in Brain Wiring of Kids With Autism: Study 3Health News:Brown Recluse Spider Bites on the Rise, Expert Warns 2Health News:Celebrity Plastic Surgery: Kim Kardashian’s Butt Tops the List of Celebrity Plastic Surgery Requests 2
... , THURSDAY, May 12 (HealthDay News) -- Heart ... high level of health literacy are more likely to continue ... with low health literacy, a new study finds. Health ... health care information. Telemonitoring systems, which help doctors monitor patients ...
... been "seizing" uncontrollably. Now a Tel Aviv University researcher ... with the uncontrolled spasms of an epileptic is not ... of the disaster. In a recent article published ... Tel Aviv University,s School of Physics and Astronomy, his ...
... HealthDay Reporter , THURSDAY, May 12 (HealthDay News) ... they are lactose-intolerant may actually suffer from a psychological ... intolerance, a person is deficient in the enzyme lactase, ... say they experience bloating, gas, gut pain and nausea ...
... News) -- Mind-body therapies such as yoga, meditation and deep-breathing ... according to a new study. Mind-body therapy is ... is rising, the researchers noted. They found that one in ... to the treatment by a medical provider. "There,s good ...
... 12, 2011 -- The American College of Physicians (ACP) ... and ACP InternistWeekly have won awards for excellence in ... from Association Media & Publishing in the Newspapers: Feature ... remote monitoring and a silver award for Best How-To ...
... German . , Neural stem cells can do a lot, ... not usually generated by neural stem cells of the peripheral nervous ... peripheral nervous system from the stem cells of the brain. However, ... and the Max Planck Institute of Immunobiology and Epigenetics in Freiburg ...
Cached Medicine News:Health News:Telemonitoring Success May Depend on Patients' Age, Literacy Level 2Health News:Diagnosing 'seizures' in the US economy 2Health News:Lactose Intolerance May Sometimes Be in the Head, Not the Gut 2Health News:Doctors Prescribing Meditation, Yoga More Often 2Health News:A new program for neural stem cells 2Health News:A new program for neural stem cells 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: